Akebia Therapeutics, Inc. is a company in the U.S. stock market and it is a holding in 42 U.S.-traded ETFs. AKBA has around 11.1M shares in the U.S. ETF market. The largest ETF holder of AKBA is the iShares Russell 2000 ETF (IWM), with approximately 2.68M shares. Investors may also find of interest that the ETF with the largest allocation to AKBA stock is Invesco Dynamic Biotechnology & Genome ETF (PBE), with a portfolio weight of 2.92%. On average, U.S. ETFs allocate 0.24% of AKBA to their portfolios.
Additionally, AKBA is a favorite stock for Vanilla and Active ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with AKBA as a holding is the Virtus LifeSci Biotech Clinical Trials ETF (BBC), with a return of 48.93%.